Hunter Associates Investment Management LLC Acquires Shares of 1,760 DexCom, Inc. (NASDAQ:DXCM)

Hunter Associates Investment Management LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 1,760 shares of the medical device company’s stock, valued at approximately $217,000.

A number of other hedge funds also recently bought and sold shares of the business. Sands Capital Management LLC increased its holdings in shares of DexCom by 4.3% during the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock worth $1,274,541,000 after buying an additional 557,543 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of DexCom by 2.1% during the 1st quarter. Geode Capital Management LLC now owns 8,282,663 shares of the medical device company’s stock worth $960,174,000 after buying an additional 170,796 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after buying an additional 73,654 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of DexCom by 1.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,033,924 shares of the medical device company’s stock worth $456,802,000 after buying an additional 44,260 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock worth $363,545,000 after buying an additional 91,249 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 2.7 %

Shares of DexCom stock traded down $3.59 during trading on Friday, hitting $130.71. 2,859,646 shares of the stock were exchanged, compared to its average volume of 2,337,474. The stock has a market cap of $50.39 billion, a price-to-earnings ratio of 99.78, a price-to-earnings-growth ratio of 2.31 and a beta of 1.20. The firm’s 50-day moving average price is $129.55 and its 200 day moving average price is $116.66. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the business earned $0.34 EPS. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. As a group, analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Raymond James increased their price objective on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $141.40.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at $36,816,646.33. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock worth $25,530,859 in the last ninety days. 0.41% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.